Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.

@article{Alotaibi2014DabigatranRA,
  title={Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.},
  author={Ghazi Alotaibi and Khalid A M Alsaleh and Cynthia Wu and Michael Sean McMurtry},
  journal={International angiology : a journal of the International Union of Angiology},
  year={2014},
  volume={33 4},
  pages={
          301-8
        }
}
AIM Many new oral anticoagulants (NOACs; dabigatran, rivaroxaban, and apixaban) are currently available to treat thromboembolic disease. There are no head-to-head trials comparing these agents. To assess the efficacy and safety of NOACs for prevention of recurrent venous thromboembolism (VTE), we performed a network meta-analysis. METHODS Medline, Embase, and the Cochrane-controlled trial register were searched, without language restriction, to identify trials. Studies were evaluated… CONTINUE READING

Similar Papers

Loading similar papers…